Cereno Scientific Broadens CS014 Focus to PH-ILD
Analysis based on 7 articles · First reported Feb 04, 2026 · Last updated Feb 04, 2026
The market is likely to react positively to Cereno Scientific's strategic decision to broaden the development focus of CS014, as it targets a severe condition with high unmet medical need and aims for faster market entry. This move could enhance investor confidence in the drug's commercial viability and the company's strategic planning.
Cereno Scientific announced a strategic shift in the development focus of its HDAC inhibitor CS014. Initially developed for idiopathic pulmonary fibrosis (IPF), CS014 will now also target pulmonary hypertension associated with interstitial lung disease (PH-ILD). This broadened focus aims to create a more clinically relevant Phase II program, strengthen CS014's development potential, and address a patient population with very high unmet medical need. According to CEO Sten R. Sörensen, this evolution is scientifically driven and is expected to accelerate CS014's path to market at a lower cost and with a higher probability of success. Rahul Agrawal, CMO and Head of R&D, emphasized that CS014 targets shared pathophysiological processes in fibrotic lung and pulmonary vascular diseases. Following a completed Phase I study with a favorable safety profile, Cereno Scientific plans to initiate a Phase II study in Q1 2027.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard